Current treatment of heart failure in the USA

References

• Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation117(4), e25–e146 (2008).
   PubMed Web of Science ®Google Scholar
• Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation112(12), e154–e235 (2005).
   PubMed Web of Science ®Google Scholar
• Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 1979 to 2004. J. Am. Coll. Cardiol.52(6), 428–434 (2008).
   PubMed Web of Science ®Google Scholar
• Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J. Card. Fail.12(1), 10–38 (2006).
   PubMed Web of Science ®Google Scholar
• Schocken DD, Benjamin EJ, Fonarow GC et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation117(19), 2544–2565 (2008).
   PubMed Web of Science ®Google Scholar
• Jessup M, Abraham WT, Casey DE et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation119(14), 1977–2016 (2009).
   PubMed Web of Science ®Google Scholar
• Hambrecht R, Gielen S, Linke A et al. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trial. JAMA283(23), 3095–3101 (2000).
   PubMed Web of Science ®Google Scholar
• Erbs S, Linke A, Gielen S et al. Exercise training in patients with severe chronic heart failure: impact on left ventricular performance and cardiac size. A retrospective analysis of the Leipzig Heart Failure Training Trial. Eur. J. Cardiovasc. Prev. Rehabil.10(5), 336–344 (2003).
   PubMedGoogle Scholar
• McKelvie RS. Exercise training in patients with heart failure: clinical outcomes, safety, and indications. Heart Fail. Rev.13(1), 3–11 (2008).
   PubMed Web of Science ®Google Scholar
• Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J.29(19), 2388–2442 (2008).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension42(6), 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110(2), 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Standards of medical care in diabetes – 2006. Diabetes Care29(Suppl. 1), S4–S42 (2006).
   PubMed Web of Science ®Google Scholar
• Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA291(11), 1358–1367 (2004).
   PubMed Web of Science ®Google Scholar
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med.316(23), 1429–1435 (1987).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med.325(5), 303–310 (1991).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moye LA et al.; The SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N. Engl. J. Med.327(10), 669–677 (1992).
   PubMed Web of Science ®Google Scholar
• The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med.325(5), 293–302 (1991).
   PubMed Web of Science ®Google Scholar
• The Acute Infarction Ramipril Efficacy (AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet342(8875), 821–828 (1993).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med.314(24), 1547–1552 (1986).
   PubMed Web of Science ®Google Scholar
• Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med.351(20), 2049–2057 (2004).
   PubMed Web of Science ®Google Scholar
• Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet355(9215), 1582–1587 (2000).
   PubMed Web of Science ®Google Scholar
• Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet362(9386), 772–776 (2003).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med.345(23), 1667–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by β-receptor blockade. Lancet1(8131), 1374–1376 (1979).
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med.334(21), 1349–1355 (1996).
   PubMed Web of Science ®Google Scholar
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet353(9146), 9–13 (1999).
   PubMed Web of Science ®Google Scholar
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet353(9169), 2001–2007 (1999).
   PubMed Web of Science ®Google Scholar
• β-blocker Evaluation of Survival trial investigators. A trial of the β-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med.344(22), 1659–1667 (2001).
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JGF et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet362(9377), 7–13 (2003).
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med.341(10), 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med.348(14), 1309–1321 (2003).
   PubMed Web of Science ®Google Scholar
• Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol.38(7), 2101–2113 (2001).
   PubMed Web of Science ®Google Scholar
• The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med.336(8), 525–533 (1997).
   PubMed Web of Science ®Google Scholar
• Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA289(7), 871–878 (2003).
   PubMed Web of Science ®Google Scholar
• Ahmed A, Pitt B, Rahimtoola SH et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int. J. Cardiol.123(2), 138–146 (2008).
   PubMed Web of Science ®Google Scholar
• Packer M, Gheorghiade M, Young JB et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE study. N. Engl. J. Med.329(1), 1–7 (1993).
   PubMed Web of Science ®Google Scholar
• Anderson JL. Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. Am. Heart J.121(6 Pt 2), 1956–1964 (1991).
   PubMed Web of Science ®Google Scholar
• Kass DA. Ventricular dyssynchrony and mechanisms of resynchronization therapy. Eur. Heart J. Suppl.4(Suppl. D), D23–D30 (2002).
   Google Scholar
• Cleland JGF, Daubert J-C, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med.352(15), 1539–1549 (2005).
   PubMed Web of Science ®Google Scholar
• Cimato TR, Jessup M. Recipient selection in cardiac transplantation: contraindications and risk factors for mortality. J. Heart Lung Transplant.21(11), 1161–1173 (2002).
   PubMed Web of Science ®Google Scholar
• Hunt SA. Comment – the REMATCH trial: long-term use of a left ventricular assist device for end-stage heart failure. J. Card. Fail.8(2), 59–60 (2002).
   PubMed Web of Science ®Google Scholar
• Slaughter MS, Rogers JG, Milano CA et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N. Engl. J. Med.361(23), 2241–2251 (2009).
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Shea AM, Milano CA et al. Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries. JAMA300(20), 2398–2406 (2008).
   PubMed Web of Science ®Google Scholar
• Bursi F, Weston SA, Redfield MM et al. Systolic and diastolic heart failure in the community. JAMA296(18), 2209–2216 (2006).
   PubMed Web of Science ®Google Scholar
• Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med.355(3), 251–259 (2006).
   PubMed Web of Science ®Google Scholar
• Bhatia RS, Tu JV, Lee DS et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N. Engl. J. Med.355(3), 260–269 (2006).
   PubMed Web of Science ®Google Scholar
• Das A, Abraham S, Deswal A. Advances in the treatment of heart failure with a preserved ejection fraction. Curr. Opin. Cardiol.23(3), 233–240 (2008).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Larson MG, Leip EP et al. Lifetime risk for developing congestive heart failure: the Framingham Heart study. Circulation106(24), 3068–3072 (2002).
   PubMed Web of Science ®Google Scholar
• Roger VL, Weston SA, Redfield MM et al. Trends in heart failure incidence and survival in a community-based population. JAMA292(3), 344–350 (2004).
   PubMed Web of Science ®Google Scholar
• Goldberg RJ, Ciampa J, Lessard D, Meyer TE, Spencer FA. Long-term survival after heart failure: a contemporary population-based perspective. Arch. Intern. Med.167(5), 490–496 (2007).
   PubMedGoogle Scholar
• Rosamond W, Flegal K, Friday G et al. Heart disease and stroke statistics – 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation115(5), e69–e171 (2007).
   PubMed Web of Science ®Google Scholar